Professor Bain provides a brief overview of his presentation at this year’s EASD conference: “Continuing the PIONEER journey”.
Speaker’s disclosures: Professor Bain has received institutional investigator fees and speaker and advisory board honoraria relating to semaglutide from Novo Nordisk.
Filmed at the European Association for the Study of Diabetes (EASD) annual meeting, Berlin, Germany, 2018
Trending Topic
After yet another successful congress, who better to reflect on the highlights than the current EASD President, Prof. Chantal Mathieu? In this interview, we explore the packed agenda, discussing everything from the prestigious prize lectures to ground-breaking research. We explore some of the most exciting data presented, including advancements in long-acting insulins, novel technologies and islet transplantation). We also touch on pivotal type 1 diabetes research (T1D), and a crucial call to action for addressing cardiovascular comorbidities in this patient population.
The FINE-HEART program aimed to evaluate the safety and efficacy of finerenone, a non-steroidal mineralocorticoid receptor antagonist (MRA), in key patient populations with type 2 diabetes, chronic kidney disease, and heart failure. By pooling data from three major Phase III trials—FINEARTS-HF, FIDELIO-DKD, and FIGARO-DKD—this comprehensive analysis sought to provide a clearer understanding of finerenone’s effects on cardiovascular mortality, renal outcomes, and hospitalizations for heart failure. The study also focused on subgroups based on diabetes control, offering valuable insights into its potential role in patients with coexisting conditions.
The latest clinical evidence surrounding the MiniMed 780G system focuses on expanding its access to younger children with type 1 diabetes. The hope is that by extending its use to children aged 2-6 years, its automated insulin delivery could significantly reduce the burden of diabetes management for families.
Dr. John Doupis (Director, Iatriko Paleou Falirou Medical Center, Diabetes Division, Athens, Greece; Editor-in-Chief, touchREVIEWS in Endocrinology) provides his top three highlights from the ADA 83rd Scientific Sessions, 2023 in the field of type 2 diabetes. Disclosures: John Doupis has received consultant ...
Prof. Chantal Mathieu (Katholieke Universiteit Leuven, Belgium) provides her highlights from the ADA 83rd Scientific Sessions, 2023 including Teplizumab, an anti-CD3 monoclonal antibody, which was the first disease modifying therapy that delays the progression from stage 2 to stage 3 type 1 diabetes and ...
The CLEAR Outcomes trial was a double-blind, randomized, placebo-controlled trial involving patients who were “statin-intolerant” and had, or were at high risk for, cardiovascular disease. The patients were assigned to receive oral bempedoic acid, 180 mg daily, or placebo. Dr. Steven ...
Orforglipron (LY3502970) is a novel oral non-peptide GLP-1 receptor agonist being developed for patients with obesity or overweight, particularly those with type-2 diabetes. Dr. Sean Wharton (Adjunct Professor at McMaster University and Medical Director of the Wharton Medical Clinic) discusses ...
The International Diabetes Federation (IDF) is the global voice of the diabetes community. They are a non-profit umbrella organisation of more than 240 national diabetes associations in 161 countries and territories, working together to improve and empower the lives of the 540 million ...
2022 saw the FDA approval of teplizumab to delay the onset of type 1 diabetes. In addition, there has also been evidence to suggest the effectivness of SGLT2 inhibitors in type 1 diabetes. We were delighted to speak with our editorial board member ...
In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) gives an overview of RocketAP and discusses how the RocketAP compares to the USS-Virginia system and also what the next steps in the clinical development of ...
An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose in the body. In this touchENDOCRINOLOGY interview, Dr José García-Tirado (University of Virginia, Charlottesville, VA, USA) discusses ...
In this touchENDOCRINOLOGY interview, Prof. Carol Levy (Icahn School of Medicine at Mount Sinai, New York City, NY, USA) discusses her study which evaluated adults with type 2 diabetes using the t:slim X2 insulin pump with Control-IQ technology to show ...
Insulin pumps are electronic devices that help you stabilise your blood glucose levels and control your diabetes. Control-IQ technology could be a powerful management solution for therapy needs of individuals living with type 2 diabetes. In this touchENDOCRINOLOGY interview, Prof. Carol ...
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Or use a .
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
